Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Corbus Pharmaceuticals Holdings (CRBP) EBIAT (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported EBIAT over the past 9 years, most recently at -$8.0 million for Q4 2023.

  • For Q4 2023, EBIAT rose 26.26% year-over-year to -$8.0 million; the TTM value through Dec 2023 reached -$44.6 million, down 5.33%, while the annual FY2024 figure was -$40.2 million, 9.85% up from the prior year.
  • EBIAT for Q4 2023 was -$8.0 million at Corbus Pharmaceuticals Holdings, up from -$10.1 million in the prior quarter.
  • Over five years, EBIAT peaked at $2.2 million in Q2 2019 and troughed at -$38.1 million in Q2 2020.
  • A 5-year average of -$15.8 million and a median of -$12.1 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: soared 117.84% in 2019 and later tumbled 1870.16% in 2020.
  • Year by year, EBIAT stood at -$26.6 million in 2019, then soared by 67.6% to -$8.6 million in 2020, then decreased by 19.15% to -$10.3 million in 2021, then decreased by 6.03% to -$10.9 million in 2022, then rose by 26.26% to -$8.0 million in 2023.
  • Business Quant data shows EBIAT for CRBP at -$8.0 million in Q4 2023, -$10.1 million in Q3 2023, and -$8.8 million in Q2 2023.